Literature DB >> 9499102

Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance.

E L Delwart1, H Pan, A Neumann, M Markowitz.   

Abstract

Plasma human immunodeficiency virus type 1 (HIV-1) populations were genetically analyzed at their most variable locus, the envelope gene, during the rapid emergence of resistance to protease inhibitor monotherapy. Plasma virus populations remained genetically constant prior to drug treatment and during the 1 to 2 weeks following initiation of therapy, while viremia fell 10- to 100-fold. Concomitant with rapid plasma viremia rebounds associated with the emergence of drug-resistant virus, marked alterations were then detected at the env locus. Plasma population changes lasted only a few weeks before the reappearance of the pretreatment envelope variants. The emergence of resistance to single protease inhibitors was therefore associated with major but transient changes at a nonselected locus. Selection for resistance to single protease inhibitors thus appears to be more complex than the continued replication of a large, random, and therefore genetically representative sampling of the pretreatment plasma population. The possibility that drug-privileged anatomical sites containing distinct envelope variants and/or a small effective HIV-1 population size account for these results is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499102      PMCID: PMC109541          DOI: 10.1128/JVI.72.3.2416-2421.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays.

Authors:  E L Delwart; H W Sheppard; B D Walker; J Goudsmit; J I Mullins
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 populations in blood and semen.

Authors:  E L Delwart; J I Mullins; P Gupta; G H Learn; M Holodniy; D Katzenstein; B D Walker; M K Singh
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

3.  Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences.

Authors:  C Power; J C McArthur; R T Johnson; D E Griffin; J D Glass; S Perryman; B Chesebro
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

4.  Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes.

Authors:  E L Delwart; E G Shpaer; J Louwagie; F E McCutchan; M Grez; H Rübsamen-Waigmann; J I Mullins
Journal:  Science       Date:  1993-11-19       Impact factor: 47.728

5.  Human immunodeficiency virus type 1 strains in the lungs of infected individuals evolve independently from those in peripheral blood and are highly conserved in the C-terminal region of the envelope V3 loop.

Authors:  S Itescu; P F Simonelli; R J Winchester; H S Ginsberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

6.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.

Authors:  D D Richman; D Havlir; J Corbeil; D Looney; C Ignacio; S A Spector; J Sullivan; S Cheeseman; K Barringer; D Pauletti
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy.

Authors:  J K Ball; E C Holmes; H Whitwell; U Desselberger
Journal:  J Gen Virol       Date:  1994-04       Impact factor: 3.891

8.  Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences.

Authors:  B T Korber; K J Kunstman; B K Patterson; M Furtado; M M McEvilly; R Levy; S M Wolinsky
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

9.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.

Authors:  I Nájera; A Holguín; M E Quiñones-Mateu; M A Muñoz-Fernández; R Nájera; C López-Galíndez; E Domingo
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Fidelity of HIV-1 reverse transcriptase copying a hypervariable region of the HIV-1 env gene.

Authors:  J Ji; L A Loeb
Journal:  Virology       Date:  1994-03       Impact factor: 3.616

View more
  18 in total

Review 1.  Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1.

Authors:  A D Kashuba; J R Dyer; L M Kramer; R H Raasch; J J Eron; M S Cohen
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.

Authors:  Magdalena Magierowska; Flavien Bernardin; Seema Garg; Silvija Staprans; Michael D Miller; Koen K A Van Rompay; Eric L Delwart
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.

Authors:  Neelanjana Ray; Jessamina E Harrison; Leslie A Blackburn; Jeffrey N Martin; Steven G Deeks; Robert W Doms
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 4.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

5.  Population genetic analysis of the protease locus of human immunodeficiency virus type 1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay.

Authors:  L Doukhan; E Delwart
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy.

Authors:  M Nijhuis; C A Boucher; P Schipper; T Leitner; R Schuurman; J Albert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

7.  Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.

Authors:  Amit Kapoor; Morris Jones; R W Shafer; Soo-Yon Rhee; Powel Kazanjian; Eric L Delwart
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment.

Authors:  Tamara Nora; Charlotte Charpentier; Olivier Tenaillon; Claire Hoede; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

9.  Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.

Authors:  Shigeyoshi Harada; Kazuhisa Yoshimura; Aki Yamaguchi; Samatchaya Boonchawalit; Keisuke Yusa; Shuzo Matsushita
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

10.  Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.

Authors:  Zandrea Ambrose; Sarah Palmer; Valerie F Boltz; Mary Kearney; Kay Larsen; Patricia Polacino; Leon Flanary; Kelli Oswald; Michael Piatak; Jeremy Smedley; Wei Shao; Norbert Bischofberger; Frank Maldarelli; Jason T Kimata; John W Mellors; Shiu-Lok Hu; John M Coffin; Jeffrey D Lifson; Vineet N KewalRamani
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.